SMAD4 Recombinant Antibody

Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4.Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80% of cases of pancreatic adenocarcinoma, but rarely in endometrial (0%), colorectal (0%), ovarian (3%), lung (0%), breast (2%) adenocarcinomas, and malignant melanoma (4%). SMAD4is an important marker for confirming a diagnosis of pancreatic adenocarcinoma.

Q13485

Mouse

Full-length human protein (amino acids 1-552) was used as the immunogen for the recombinant SMAD4 antibody.

Monoclonal

IgG1 κ

Recombinant

IHC-P

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

Aliquot the recombinant SMAD4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

This recombinant SMAD4 antibody is available for research use only.